RY-103

N/A

Report date: 2025/03/10 10:30:58
First In Class

Base Information

Drug NameRY-103
Drug Alias NameNS-101RY-103
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-TAFA Chemokine Like Family Member 5
TargetsTAFA Chemokine Like Family Member 5
Therapy Area/IndicationsNeurodegenerative DiseasesFrontotemporal DementiaAlzheimer Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNeuracle Science Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKonkuk University Medical CenterNeuracle Science Co Ltd
Inactive CompaniesN/A
Active IndicationsNeurodegenerative DiseasesFrontotemporal DementiaAlzheimer Disease +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A